Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG200745 PPA in Myelodysplastic Syndrome Patients After Hypomethylating Therapy Failure
KCT0002194Phase 2Recruiting
- Sponsor
- Crystal Genomics
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivaltinostat in myelodysplastic syndrome (MDS), sponsored by Crystal Genomics. Started Jun 2016; status: recruiting.
02
Drugs
ivaltinostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on KCT0002194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002194.